دورية أكاديمية
أعرض في EDS

Role of P2X7 Receptors in Immune Responses During Neurodegeneration.

التفاصيل البيبلوغرافية
العنوان: Role of P2X7 Receptors in Immune Responses During Neurodegeneration.
المؤلفون: Oliveira-Giacomelli Á; Department of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil., Petiz LL; Department of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil., Andrejew R; Department of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil., Turrini N; Department of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil., Silva JB; Department of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil., Sack U; Institute of Clinical Immunology, Medical Faculty, University of Leipzig, Leipzig, Germany., Ulrich H; Department of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil.; Institute of Clinical Immunology, Medical Faculty, University of Leipzig, Leipzig, Germany.
المصدر: Frontiers in cellular neuroscience [Front Cell Neurosci] 2021 May 26; Vol. 15, pp. 662935. Date of Electronic Publication: 2021 May 26 (Print Publication: 2021).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101477935 Publication Model: eCollection Cited Medium: Print ISSN: 1662-5102 (Print) Linking ISSN: 16625102 NLM ISO Abbreviation: Front Cell Neurosci Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Lausanne, Switzerland : Frontiers Research Foundation, 2007-
مستخلص: P2X7 receptors are ion-gated channels activated by ATP. Under pathological conditions, the extensive release of ATP induces sustained P2X7 receptor activation, culminating in induction of proinflammatory pathways with inflammasome assembly and cytokine release. These inflammatory conditions, whether occurring peripherally or in the central nervous system (CNS), increase blood-brain-barrier (BBB) permeability. Besides its well-known involvement in neurodegeneration and neuroinflammation, the P2X7 receptor may induce BBB disruption and chemotaxis of peripheral immune cells to the CNS, resulting in brain parenchyma infiltration. For instance, despite common effects on cytokine release, P2X7 receptor signaling is also associated with metalloproteinase secretion and activation, as well as migration and differentiation of T lymphocytes, monocytes and dendritic cells. Here we highlight that peripheral immune cells mediate the pathogenesis of Multiple Sclerosis and Parkinson's and Alzheimer's disease, mainly through T lymphocyte, neutrophil and monocyte infiltration. We propose that P2X7 receptor activation contributes to neurodegenerative disease progression beyond its known effects on the CNS. This review discusses how P2X7 receptor activation mediates responses of peripheral immune cells within the inflamed CNS, as occurring in the aforementioned diseases.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Oliveira-Giacomelli, Petiz, Andrejew, Turrini, Silva, Sack and Ulrich.)
References: Science. 1992 Apr 10;256(5054):184-5. (PMID: 1566067)
Neural Plast. 2016;2016:8928530. (PMID: 27795859)
J Neurosci. 2014 Aug 6;34(32):10528-40. (PMID: 25100587)
Purinergic Signal. 2007 Mar;3(1-2):1-3. (PMID: 18404413)
Mol Psychiatry. 2021 Apr;26(4):1044-1059. (PMID: 33328588)
Trends Cell Biol. 2018 May;28(5):392-404. (PMID: 29439897)
Front Immunol. 2020 Jun 10;11:1179. (PMID: 32587592)
J Neurotrauma. 2002 Nov;19(11):1411-9. (PMID: 12490006)
Immunometabolism. 2019;1(1):. (PMID: 31428464)
Front Immunol. 2017 Nov 15;8:1529. (PMID: 29187851)
Mol Neurobiol. 2016 Mar;53(2):1181-1194. (PMID: 25598354)
Neuroscience. 2007 Dec 5;150(2):498-509. (PMID: 17945430)
J Neurosci Res. 2009 Feb 15;87(3):653-9. (PMID: 18816791)
FASEB J. 2009 Jun;23(6):1685-93. (PMID: 19211924)
Biochem Biophys Res Commun. 2005 Jun 24;332(1):17-27. (PMID: 15896293)
Stem Cell Rev Rep. 2019 Aug;15(4):497-505. (PMID: 31020518)
Nature. 2018 Jul;559(7713):264-268. (PMID: 29973721)
Front Cell Neurosci. 2019 Nov 08;13:476. (PMID: 31787881)
Science. 2011 Sep 9;333(6048):1456-8. (PMID: 21778362)
J Neurochem. 2010 Aug;114(3):810-9. (PMID: 20477948)
Cell. 2017 Jun 15;169(7):1276-1290.e17. (PMID: 28602351)
Eur J Pharmacol. 2020 Dec 5;888:173460. (PMID: 32805257)
Neurochem Int. 2005 Nov;47(6):442-8. (PMID: 16029911)
J Neurochem. 2006 Nov;99(3):745-58. (PMID: 16836656)
J Immunol. 1998 Oct 1;161(7):3767-75. (PMID: 9759903)
Nat Neurosci. 2011 Oct 26;14(11):1398-1405. (PMID: 22030551)
Brain Res Bull. 2000 Mar 15;51(5):363-9. (PMID: 10715555)
J Neurochem. 2002 Jun;81(6):1196-211. (PMID: 12068068)
Front Neurosci. 2019 Dec 04;13:1291. (PMID: 31866808)
Nat Med. 2015 Aug;21(8):880-6. (PMID: 26214837)
Mol Neurobiol. 2017 Aug;54(6):4486-4495. (PMID: 27356916)
Int J Mol Sci. 2020 Jul 13;21(14):. (PMID: 32668623)
J Immunol. 2004 Mar 15;172(6):3399-405. (PMID: 15004138)
Purinergic Signal. 2018 Dec;14(4):385-393. (PMID: 30091000)
Nat Rev Immunol. 2011 Mar;11(3):201-12. (PMID: 21331080)
Mol Biol Cell. 2000 Dec;11(12):4131-42. (PMID: 11102513)
Cell Tissue Res. 2014 Mar;355(3):687-99. (PMID: 24590145)
Curr Drug Targets CNS Neurol Disord. 2003 Dec;2(6):403-12. (PMID: 14683468)
BMC Neurol. 2006 Mar 02;6:12. (PMID: 16512913)
Front Cell Neurosci. 2018 Dec 18;12:488. (PMID: 30618635)
Nature. 2010 Nov 25;468(7323):557-61. (PMID: 20944627)
Sci Immunol. 2019 Sep 6;4(39):. (PMID: 31492708)
Front Immunol. 2014 Nov 26;5:603. (PMID: 25505468)
Purinergic Signal. 2012 Sep;8(3):579-86. (PMID: 22476940)
Mini Rev Med Chem. 2020;20(9):754-767. (PMID: 31686637)
J Neurochem. 2016 Oct;139 Suppl 1:27-58. (PMID: 27381749)
J Neurosci. 2007 Aug 29;27(35):9525-33. (PMID: 17728465)
Nat Immunol. 2016 Jul;17(7):797-805. (PMID: 27135602)
Blood. 2011 Sep 8;118(10):2906-17. (PMID: 21778339)
Science. 2020 Jan 31;367(6477):528-537. (PMID: 31831638)
Cell. 2015 Nov 19;163(5):1064-1078. (PMID: 26590417)
Neuron. 2010 Jan 14;65(1):94-106. (PMID: 20152116)
Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2051-2064. (PMID: 31243495)
Glia. 2005 Jan 15;49(2):245-58. (PMID: 15472991)
Nat Rev Neurol. 2018 Jan;14(1):22-39. (PMID: 29242522)
J Exp Med. 2014 Jul 28;211(8):1533-49. (PMID: 25002752)
Parkinsons Dis. 2012;2012:214714. (PMID: 22548201)
J Neurosci. 2007 May 2;27(18):4957-68. (PMID: 17475804)
J Biol Chem. 2001 Jan 5;276(1):125-32. (PMID: 11016935)
Neuron. 2010 Nov 4;68(3):409-27. (PMID: 21040844)
J Neuroinflammation. 2008 Feb 27;5:8. (PMID: 18304357)
J Biol Chem. 2012 Mar 23;287(13):10650-10663. (PMID: 22235111)
Trends Pharmacol Sci. 2017 Mar;38(3):291-304. (PMID: 28017362)
Front Pharmacol. 2017 Mar 16;8:123. (PMID: 28360855)
Nat Immunol. 2018 Oct;19(10):1048-1058. (PMID: 30250185)
Sci Rep. 2016 Mar 16;6:23286. (PMID: 26980524)
J Neurosci. 2004 Jan 7;24(1):1-7. (PMID: 14715932)
Nature. 2016 Jul 06;535(7610):153-8. (PMID: 27383986)
J Exp Med. 2006 Apr 17;203(4):1007-19. (PMID: 16585265)
Neurobiol Aging. 2010 Jan;31(1):8-16. (PMID: 18440671)
Front Mol Neurosci. 2020 Jul 31;13:124. (PMID: 32848594)
Nat Rev Neurosci. 2011 Nov 03;12(12):723-38. (PMID: 22048062)
Lancet Neurol. 2015 Apr;14(4):388-405. (PMID: 25792098)
Front Immunol. 2020 Dec 07;11:609441. (PMID: 33424864)
J Cereb Blood Flow Metab. 2001 Dec;21(12):1393-400. (PMID: 11740200)
Brain Behav Immun. 2015 Aug;48:31-41. (PMID: 25678162)
EMBO Mol Med. 2019 Jun;11(6):. (PMID: 31015277)
Front Neurosci. 2014 Oct 22;8:338. (PMID: 25374504)
Neuron. 2017 Sep 27;96(1):17-42. (PMID: 28957666)
Neuroimmunomodulation. 1996 Mar-Jun;3(2-3):69-75. (PMID: 8945720)
J Immunol. 2013 Feb 15;190(4):1551-9. (PMID: 23319734)
J Cell Physiol. 1996 Mar;166(3):637-42. (PMID: 8600168)
J Neuroinflammation. 2010 Jan 04;7:1. (PMID: 20047691)
Stem Cells. 2010 Feb;28(2):329-43. (PMID: 20014009)
Front Mol Neurosci. 2018 Jan 04;10:421. (PMID: 29354029)
Nat Rev Neurol. 2010 Jul;6(7):393-403. (PMID: 20551947)
Sci Rep. 2016 Mar 03;6:22586. (PMID: 26935289)
Blood. 2006 Jun 15;107(12):4946-53. (PMID: 16514055)
J Neuroimmunol. 2011 Aug 15;237(1-2):73-9. (PMID: 21737148)
Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6362-7. (PMID: 16571660)
Brain Res. 2014 Mar 6;1550:1-8. (PMID: 24418464)
FASEB J. 2010 Sep;24(9):3393-404. (PMID: 20453110)
Nature. 2017 Jun 29;546(7660):656-661. (PMID: 28636593)
J Neurochem. 2009 Jan;108(1):115-25. (PMID: 19014371)
J Neurosci Res. 2000 Jul 15;61(2):212-24. (PMID: 10878594)
Acta Neuropathol. 2016 Sep;132(3):377-89. (PMID: 27411339)
Dev Neurobiol. 2011 Nov;71(11):1018-39. (PMID: 21780303)
Neurobiol Aging. 2015 Jul;36(7):2304-2318. (PMID: 25983062)
Free Radic Biol Med. 2005 Jul 1;39(1):71-80. (PMID: 15925279)
Front Pharmacol. 2018 Feb 06;9:52. (PMID: 29467654)
Cell Rep. 2019 Apr 2;27(1):1-10.e4. (PMID: 30943393)
Front Immunol. 2016 Nov 04;7:480. (PMID: 27867386)
Front Immunol. 2019 Apr 16;10:790. (PMID: 31040847)
Biochim Biophys Acta. 2016 Mar;1862(3):461-71. (PMID: 26527183)
Am J Physiol. 1995 Oct;269(4 Pt 1):G467-75. (PMID: 7485497)
Autoimmun Rev. 2019 Aug;18(8):767-777. (PMID: 31181327)
J Immunol. 2011 Sep 1;187(5):2365-75. (PMID: 21821797)
Brain Struct Funct. 2014 Jan;219(1):151-70. (PMID: 23262920)
PLoS One. 2015 Apr 17;10(4):e0124362. (PMID: 25884837)
Physiol Rev. 2019 Jan 1;99(1):21-78. (PMID: 30280653)
J Neuroinflammation. 2020 Feb 18;17(1):64. (PMID: 32070376)
Cell Res. 2015 Dec;25(12):1285-98. (PMID: 26611636)
Glia. 2014 Apr;62(4):592-607. (PMID: 24470356)
Immunity. 2017 Jul 18;47(1):15-31. (PMID: 28723547)
Nat Neurosci. 2018 Apr;21(4):530-540. (PMID: 29472620)
Fluids Barriers CNS. 2011 Jan 18;8(1):8. (PMID: 21349156)
J Neuroinflammation. 2017 Jul 17;14(1):135. (PMID: 28716092)
Br J Pharmacol. 2018 Nov;175(22):4195-4208. (PMID: 30098011)
Neuroreport. 2010 Sep 15;21(13):865-70. (PMID: 20639779)
Nat Rev Immunol. 2017 Mar;17(3):179-194. (PMID: 28138136)
Dev Dyn. 2020 Jun;249(6):723-740. (PMID: 32072708)
J Cell Sci. 2012 Aug 15;125(Pt 16):3776-89. (PMID: 22553206)
Sci Rep. 2016 Sep 09;6:32900. (PMID: 27610547)
Annu Rev Neurosci. 2008;31:247-69. (PMID: 18558855)
Nat Neurosci. 2017 Feb;20(2):136-144. (PMID: 28092660)
J Immunol. 2005 Jun 1;174(11):7268-77. (PMID: 15905573)
Purinergic Signal. 2020 Jun;16(2):153-166. (PMID: 32415576)
Neuropharmacology. 2014 Jun;81:142-52. (PMID: 24508709)
J Immunol. 2009 Apr 1;182(7):4378-85. (PMID: 19299738)
Eur J Nucl Med Mol Imaging. 2020 Feb;47(2):379-389. (PMID: 31705174)
J Exp Med. 2017 Nov 6;214(11):3151-3169. (PMID: 29061693)
J Immunol. 2001 Oct 15;167(8):4644-50. (PMID: 11591794)
Front Pharmacol. 2019 Aug 23;10:840. (PMID: 31507408)
Brain Neurosci Adv. 2018 Dec 6;2:2398212818817494. (PMID: 32166165)
J Neuropathol Exp Neurol. 2006 Nov;65(11):1090-7. (PMID: 17086106)
Microvasc Res. 2019 Jul;124:61-66. (PMID: 30885616)
J Neurosci. 2001 Sep 15;21(18):7135-42. (PMID: 11549724)
Nat Med. 2017 Sep 8;23(9):1018-1027. (PMID: 28886007)
J Neuroimmunol. 2002 Mar;124(1-2):83-92. (PMID: 11958825)
Trends Immunol. 2007 Jan;28(1):5-11. (PMID: 17140851)
J Immunol. 2006 Mar 1;176(5):3115-26. (PMID: 16493071)
Neuropharmacology. 1997 Sep;36(9):1277-83. (PMID: 9364482)
J Neuroinflammation. 2008 Aug 08;5:33. (PMID: 18691411)
J Neuroimmunol. 2002 Jan;122(1-2):1-8. (PMID: 11777538)
Brain. 2020 Dec 1;143(12):3717-3733. (PMID: 33118032)
Am J Physiol Cell Physiol. 2001 Apr;280(4):C943-53. (PMID: 11245611)
Neurochem Int. 2010 Dec;57(7):823-9. (PMID: 20817062)
BMC Immunol. 2012 Dec 04;13:64. (PMID: 23210974)
Neuroscience. 2020 Apr 1;431:73-85. (PMID: 32036014)
Vascul Pharmacol. 2002 Jun;38(6):315-22. (PMID: 12529926)
EMBO J. 2016 Aug 15;35(16):1766-78. (PMID: 27418190)
Mol Psychiatry. 2019 Jan;24(1):108-125. (PMID: 29934546)
Nat Commun. 2020 Apr 20;11(1):1875. (PMID: 32313102)
Pharmacol Rev. 2014 Jul;66(3):638-75. (PMID: 24928329)
Immunology. 2018 Jun;154(2):204-219. (PMID: 29513402)
J Neural Transm (Vienna). 2010 Jun;117(6):681-7. (PMID: 20387084)
Pain. 2005 Apr;114(3):386-396. (PMID: 15777864)
Front Integr Neurosci. 2014 Jan 10;7:80. (PMID: 24454281)
Adv Pharmacol. 2011;61:333-72. (PMID: 21586364)
Naunyn Schmiedebergs Arch Pharmacol. 2013 Sep;386(9):775-87. (PMID: 23657251)
Int Immunol. 2006 Jul;18(7):1171-8. (PMID: 16740600)
Nature. 2010 Nov 25;468(7323):562-6. (PMID: 20944625)
Science. 2011 Dec 23;334(6063):1727-31. (PMID: 22144466)
J Cell Biol. 2003 May 12;161(3):653-60. (PMID: 12743111)
Brain. 2000 Apr;123 ( Pt 4):698-709. (PMID: 10734001)
Brain Behav Immun Health. 2020 Mar 28;4:100062. (PMID: 34589847)
Front Neurosci. 2019 Jul 31;13:799. (PMID: 31417352)
Brain Behav Immun. 2010 May;24(4):641-51. (PMID: 20138983)
J Neurosci. 2009 Mar 25;29(12):3781-91. (PMID: 19321774)
Exp Neurol. 2001 Apr;168(2):242-9. (PMID: 11259112)
J Cereb Blood Flow Metab. 2010 Dec;30(12):1939-50. (PMID: 20354546)
Blood. 2010 Feb 25;115(8):1621-31. (PMID: 20007545)
Nat Neurosci. 2016 Jul 26;19(8):987-91. (PMID: 27459405)
Sci Rep. 2021 Jan 13;11(1):1120. (PMID: 33441868)
Blood. 1998 Aug 1;92(3):946-51. (PMID: 9680363)
J Neuroimmunol. 1998 Apr 15;84(2):238-49. (PMID: 9628469)
Cell Rep. 2013 Nov 14;5(3):646-53. (PMID: 24210819)
Int J Neuropsychopharmacol. 2014 Aug;17(8):1243-55. (PMID: 24626059)
J Leukoc Biol. 2011 Apr;89(4):539-56. (PMID: 21169520)
Br J Pharmacol. 2012 Feb;165(4):978-93. (PMID: 21838754)
Front Pharmacol. 2018 Feb 01;9:30. (PMID: 29449810)
BMC Immunol. 2002 Aug 26;3:11. (PMID: 12196270)
Lancet Neurol. 2009 Feb;8(2):205-16. (PMID: 19161911)
فهرسة مساهمة: Keywords: P2X7 receptors; blood brain barrier; microglia; neurodegeneration; peripheral immune system
تواريخ الأحداث: Date Created: 20210614 Latest Revision: 20240402
رمز التحديث: 20240402
مُعرف محوري في PubMed: PMC8187565
DOI: 10.3389/fncel.2021.662935
PMID: 34122013
قاعدة البيانات: MEDLINE
الوصف
تدمد:1662-5102
DOI:10.3389/fncel.2021.662935